Open AccessIncidence and survival of hematological cancers among adults ages ≥75 years
Author(s) -
KrokSchoen Jessica L.,
Fisher James L.,
Stephens Julie A.,
Mims Alice,
Ayyappan Sabarish,
Woyach Jennifer A.,
Rosko Ashley E.
Publication year - 2018
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1461
Subject(s) - medicine , relative survival , incidence (geometry) , myeloid leukemia , multiple myeloma , epidemiology , chronic lymphocytic leukemia , hematologic malignancy , population , leukemia , lymphoma , young adult , cancer , cancer registry , physics , environmental health , optics
Evaluating population‐based data of hematologic malignancies ( HM s) in older adults provides prognostic information for this growing demographic. Incidence rates and one‐ and five‐year relative survival rates were examined for specific HM s among adults ages ≥75 years using data from the Surveillance, Epidemiology and End Results ( SEER ) Program. Hematologic malignancy cases (Hodgkin lymphoma ( HL ), non‐Hodgkin lymphoma ( NHL ), multiple myeloma ( MM ), acute lymphocytic leukemia ( ALL ), chronic lymphocytic leukemia ( CLL ), acute myeloid leukemia ( AML ), and chronic myeloid leukemia ( CML )) were reported to one of 18 SEER registries. Recent average annual (2010–2014) incidence rates and incidence trends from 1973 to 2014 were examined for cases ages ≥75 years. One‐ and five‐year relative cancer survival rates were examined for adults ages ≥75 years diagnosed 2007–2013, with follow‐up into 2014. From 1973 to 2014, incidence rates increased for NHL , MM , and AML , decreased for HL , and remained relatively stable for ALL , CLL , and CML among adults ages ≥75 years. The highest one‐ and five‐year relative survival rates were observed among adults with CLL ages 75–84 years (1 year: 91.8% (95% CI = 91.8–90.8)) and 5 years: 76.5% (95% CI = 74.2–78.6)). The lowest one‐ and five‐year survival rates were observed among adults with AML ages 75–84 (1 year: 18.2% (95% CI = 74.2–78.6) and 5 years: 2.7% (95% CI = 2.0–3.6)). Survival for older adults ages ≥75 years with HM s is poor, particularly for acute leukemia. Understanding the heterogeneity in HM outcomes among older patients may help clinicians better address the hematological cancer burden and mortality in the aging population.